TriPath Imaging in preferred provider deal:
This article was originally published in Clinica
TriPath Imaging has formed an agreement with the San Antonio, Texas-based International Cancer Screening Laboratory for the use of TriPath's AutoCyte PREP system for the detection of cervical cancer. Under the agreement, Burlington, North Carolina-based TriPath becomes ICSL's preferred provider of thin-layer preparations for three years. ICSL processes over 500,000 Pap tests annually.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.